SHILPAMED Q2 FY27 Results & Earnings Analysis
Sentiment: Great (Confidence: high)
Earnings Summary
Shilpa Medicare delivered record Q2 FY27 revenues of INR538 crores (up 35% YoY) and H1 revenues of INR1,007 crores (up 44% YoY), with highest ever EBITDA and PAT. All four business segments (API, Formulation, Biologics, CDMO) contributed to growth. Gross margins declined ~700 bps due to higher API sales mix and raw material cost inflation. Management is investing in peptide capacity, biosimilars, and complex formulations, with multiple launches and partner program commercializations expected in FY28 and beyond. ROCE improved to 13.3% (adjusted 18.3%). Management expressed confidence in continuing momentum, though specific guidance was not provided.
Management Tone
- Prepared Remarks: Great — Prepared remarks emphasized record performance, all four engines firing, and a dense pipeline of differentiated launches with strong confidence.
- Q&A Session: Good — Analysts asked about margin decline, peptide capex, biosimilar timelines, and regulatory risks; management responded directly on most points, though some forward-looking details were withheld due to confidentiality or lack of guidance. No material negatives emerged.
Revenue Growth Drivers
- Improved uptake of key API products from newly expanded capacities
- Complex finished dosage formulation portfolio in EU, US, and RoW, including new launches
- Nor-UDCA first-in-class launch in India driving 2.5x growth in India business
Growth vs Margin Focus
Management emphasized growth through multiple engines and new launches while also highlighting operating leverage, ROCE improvement, and focus on high gross margin businesses (peptides, oncology APIs, CDMO). They expect ROCE to improve as capacities fill.
About Shilpa Medicare Limited
Shilpa Medicare Limited (SHILPAMED) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.